Cathie Wood's ARK Boosts CRISPR Stock with Significant Buy

Cathie Wood's ARK Invest has made a significant investment in CRISPR Therapeutics, a biotechnology company focused on gene editing. According to a report by Investing.com, ARK Invest has acquired a substantial amount of CRISPR Therapeutics stock, boosting the company's shares.

CRISPR Therapeutics is a leading player in the gene editing space, with its technology having the potential to revolutionize the treatment of genetic diseases. The company's shares have been on a rollercoaster ride in recent times, with significant fluctuations in price.

ARK Invest's significant buy in CRISPR Therapeutics has sent the company's shares soaring, with a significant increase in price. This move by ARK Invest is seen as a vote of confidence in CRISPR Therapeutics' technology and its potential to make a significant impact in the field of gene editing.

The investment by ARK Invest is a significant development in the gene editing space, with the potential to drive growth and innovation in the industry. As a leading player in the space, CRISPR Therapeutics is poised to make a significant impact in the treatment of genetic diseases.

Sources

[1] Cathie Wood’s ARK boosts CRISPR stock with significant buy